Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.
“Taken together, these results indicate that, once PNP or NNP patients develop neuro-PASC, whether they contracted SARS-CoV-2 infection prior to, or after SARS-CoV-2 vaccination makes little ...
ONS-5010 is an investigational ophthalmic formulation of bevacizumab, a vascular endothelial growth factor inhibitor, under development as an intravitreal injection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback